Definium Therapeutics (DFTX) Common Equity (2019 - 2026)

Definium Therapeutics (DFTX) has 8 years of Common Equity data on file, last reported at $278.8 million in Q1 2026.

• Common Equity for Q1 2026 came in at $278.8 million, up 25.15% year-over-year; the trailing twelve-month figure through Mar 2026 was $278.8 million (up 25.15% YoY), and the FY2025 annual result was $332.3 million, up 37.64% from the prior year.
• Common Equity retreated to $278.8 million in Q1 2026 per DFTX's latest filing, from $332.3 million in the prior quarter.
• Over five years, Common Equity peaked at $332.3 million in Q4 2025 and troughed at $78.1 million in Q4 2023.
• A 5-year average of $178.1 million and a median of $153.6 million in 2022 frame the typical range for Common Equity.
• The sharpest annual moves came in 2024 and 2025: Common Equity surged 209.02% in 2024, then sank 50.19% in 2025.
• A 5-year view of Common Equity shows it stood at $150.9 million in 2022, then sank by 48.23% to $78.1 million in 2023, then surged by 209.02% to $241.4 million in 2024, then soared by 37.64% to $332.3 million in 2025, then slipped by 16.09% to $278.8 million in 2026.
• Business Quant data shows DFTX's Common Equity at $278.8 million in Q1 2026, $332.3 million in Q4 2025, and $130.6 million in Q3 2025.